Inoviq Ltd
IIQ
Company Profile
Business description
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.
Contact
Sector
Healthcare
Stock type
Industry
Diagnostics & Research
Fiscal Year End
Employees
Stocks News & Analysis
stocks
After earnings is Apple stock a buy, sell or fairly valued?
Our thoughts on Apple's stock amid slowing iPhone sales but high services revenue.
stocks
Ask the analyst: Is the market underestimating Bapcor?
This moated ASX company's shares are in a prolonged slump. I quizzed our analyst Angus Hewitt on its management, the potential impact of EVs, and more.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,753.30 | 1.70 | 0.02% |
| CAC 40 | 8,028.90 | 22.68 | 0.28% |
| DAX 40 | 22,037.83 | 126.09 | 0.58% |
| Dow JONES (US) | 44,593.65 | 123.24 | 0.28% |
| FTSE 100 | 8,777.39 | 9.59 | 0.11% |
| HKSE | 21,294.86 | 227.12 | -1.06% |
| NASDAQ | 19,643.86 | 70.41 | -0.36% |
| Nikkei 225 | 38,801.17 | 14.15 | 0.04% |
| NZX 50 Index | 12,893.31 | 24.14 | -0.19% |
| S&P 500 | 6,068.50 | 2.06 | 0.03% |
| S&P/ASX 200 | 8,486.60 | 2.60 | 0.03% |
| SSE Composite Index | 3,318.06 | 4.11 | -0.12% |